Evotec SE 6-K, filed Aug 13, 2025

Evotec SE (EVO)

6-K 2025-08-13 For: 2025-08-13

View Original

Added on April 06, 2026

About this 6-K

Evotec SE filed this 6-K on August 13, 2025.

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Exhibit	Description of Exhibit
99.1	Evotec SE reports H1 2025 results: Strong progress on strategy execution

	Evotec SE

	By:	/s/ Paul Hitchin
		Name: Paul Hitchin
		Title: Chief Financial Officer

	Six months ended June 30, 2025
in k€	Discovery and Preclinical Development¹			Just – Evotec Biologics			Intersegment eliminations			Evotec Group
Revenues²		268,969			102,244			—			371,213
Intersegment revenues		29			23			(52	)		—
Costs of revenue		(242,509	)		(92,937	)		52			(335,393	)
Gross profit		26,490			9,330			—			35,820
Gross margin %		10	%		9	%		—	%		10	%

Research and development cost		(18,907	)		(62	)		—			(18,969	)
Selling, general and administrative cost		(73,676	)		(15,631	)		—			(89,308	)
Other operating income		27,885			1,756			—			29,642
Other operating expenses		(5,066	)		(535	)		—			(5,601	)
Reorganization costs		634			—			—			634
Operating Loss		(42,641	)		(5,141	)		—			(47,782	)

Adjusted EBITDA³		(9,329	)		7,478			—			(1,850	)

	Six months ended June 30, 2024
in k€	Discovery and Preclinical Development¹			Just – Evotec Biologics			Intersegment eliminations			Evotec Group
Revenues²		302,379			88,471			—			390,850
Intersegment revenues		—			453			(453	)		—
Costs of revenue		(259,536	)		(81,017	)		204			(340,348	)
Gross profit		42,843			7,907			(249	)		50,501
Gross margin %		14	%		9	%		—	%		13	%

Research and development expenses		(29,348	)		(154	)		249			(29,253	)
Selling, general and administrative expenses		(74,859	)		(17,046	)		—			(91,905	)
Other operating income		23,127			1,106			—			24,233
Other operating expenses		(7,933	)		—			—			(7,933	)
Reorganization costs		(67,447	)		(1,009	)		—			(68,456	)
Operating Loss		(113,617	)		(9,196	)		—			(122,813	)

Adjusted EBITDA³		(3,767	)		3,300			—			(467	)

	Shares			(thereof, restricted Shares from STI Payout)		Outstanding Shares from vested SPA's		Granted unvested SPA's (total)		Outstanding Shares from vested RSA's		Granted unvested RSA's (total)
Management Board
Dr Christian Wojczewski		50,000			—		—		183,113		—		—
Dr Cord Dohrmann		191,084			10,679		—		166,202		—		29,851
Aurélie Dalbiez		3,500			—		—		74,390		—		—
Paul Hitchin		—			—		—		90,921		—		—

Supervisory Board
Prof. Dr Iris Löw-Friedrich		15,000			—		—		—		—		—
Roland Sackers		—			—		—		—		—		—
Camilla Macapili Languille		—			—		—		—		—		—
Dr Constanze Ulmer-Eilfort		—			—		—		—		—		—
Wesley Wheeler		3,188	*		—		—		—		—		—
Dr Duncan McHale		—			—		—		—		—		—

in k€ except share and per share data	Six months ended June 30, 2025			Six months ended June 30, 2024			Three months ended June 30, 2025			Three months ended June 30, 2024
Revenue		371,213			390,850			171,235			182,123
Costs of revenue		(335,393	)		(340,348	)		(162,641	)		(166,382	)
Gross profit		35,820			50,501			8,594			15,742

Operating income (expense)
— Research and development		(18,969	)		(29,253	)		(8,211	)		(13,011	)
— Selling, general and administrative expenses		(89,308	)		(91,905	)		(41,610	)		(45,969	)
— Other operating income		29,642			24,233			16,665			11,552
— Other operating expenses		(5,601	)		(7,933	)		(4,037	)		(4,464	)
— Impairment of intangible assets		—			—			—			—
— Reorganization costs		634			(68,456	)		826			(68,456	)
Total operating income (expense)		(83,602	)		(173,314	)		(36,367	)		(120,347	)
Operating income (loss)		(47,782	)		(122,813	)		(27,773	)		(104,606	)

Non-operating income (expense)
Gain (loss) on investment in financial instruments reevaluation		427			(8,555	)		427			(393	)
Share of profit (loss) and reevaluation of at-equity investments		(1,217	)		403			(646	)		1,454
Other financial income		2,422			1,884			1,206			467
Other financial expense		(8,402	)		(5,416	)		(5,995	)		(2,743	)
Other non-operating income (expense)		(18,719	)		3,260			(10,637	)		1,366
Total non-operating income (expense)		(25,488	)		(8,423	)		(15,645	)		151

Net income (loss) before taxes		(73,270	)		(131,236	)		(43,419	)		(104,455	)
— Income taxes		(1,785	)		15,632			(59	)		9,523
Net income (loss)		(75,055	)		(115,605	)		(43,478	)		(94,932	)

Weighted average shares outstanding		177,561,699			177,242,377			177,596,911			177,303,470
Net result per share (basic)		(0.42	)		(0.65	)		(0.24	)		(0.54	)
Net result per share (diluted)		(0.42	)		(0.65	)		(0.24	)		(0.54	)

in k€	Six months ended June 30, 2025			Six months ended June 30, 2024			Three months ended June 30, 2025			Three months ended June 30, 2024
Net income (loss)		(75,055	)		(115,605	)		(43,478	)		(94,932	)
Accumulated other comprehensive income
Items which are not re-classified to the income statement
Revaluation of equity investments		(846	)		(3,856	)		(50	)		(2,134	)

Items which have to be re-classified to the income statement at a later date
Foreign currency translation		(35,397	)		11,176			(24,611	)		3,995
Revaluation and disposal of other short-term investments		1,108			(1,382	)		581			(3,649	)

Other comprehensive income (loss)		(35,135	)		5,938			(24,079	)		(1,788	)
Total comprehensive income (loss)		(110,190	)		(109,667	)		(67,557	)		(96,720	)

in k€	as of June 30, 2025		as of December 31, 2024
ASSETS
Current Assets:
— Cash and cash equivalents		267,825		306,387
— Investments		80,176		90,413
— Trade and other receivables		85,165		116,319
— Contract assets		48,856		46,034
— Inventories		34,563		31,122
— Current tax assets		34,564		41,879
— Other current financial assets including derivatives		8,396		4,290
— Prepaid expenses and other current assets		44,901		45,519
Total current assets		604,446		681,964

Non-current assets:
— Non-current investments and other non-current financial assets		48,346		40,014
— Investments in associates and Joint ventures		4,497		2,138
— Property, plant and equipment		782,702		823,937
— Intangible assets and Goodwill		304,294		309,295
— Deferred tax assets		16,625		17,333
— Non-current tax assets		46,343		34,357
— Other non-current assets		1,007		3,464
Total non-current assets		1,203,813		1,230,538
Total assets		1,808,259		1,912,502

	Share capital						Income and expense recognised in other comprehensive income
in k€ except share data	Shares		Amount		Additional paid-in capital		Foreign currency translation			Revaluation reserve			Retained Earnings			Total stockholders' equity
Balance at January 1, 2024		177,185,736		177,186		1,449,654		(18,049	)		(12,594	)		(476,290	)		1,119,908
Exercised stock options		367,648		368		153		—			—			—			521
Stock option plan		—		—		705		—			—			—			705
Other comprehensive income		—		—		—		11,176			(5,238	)		—			5,938
Net income (loss) for the period		—		—		—		—			—			(115,605	)		(115,605	)
Total comprehensive income (loss)		—		—		—		11,176			(5,238	)		(115,605	)		(109,667	)
Balance at June 30, 2024		177,553,384		177,553		1,450,512		(6,873	)		(17.832	)		(591,895	)		1,011,466

Balance at January 1, 2025		177,553,456		177,553		1,454,688		5,078			(12,427	)		(672,370	)		952,525
Exercised stock options		213,085		213		—		—			—			—			213
Stock option plan		—		—		3,239		—			—			—			3,239
Other comprehensive income		—		—		—		(35,397	)		262			—			(35,135	)
Net income (loss) for the period		—		—		—		—			—			(75,055	)		(75,055	)
Total comprehensive income (loss)		—		—		—		(35,397	)		262			(75,055	)		(110,190	)
Balance at June 30, 2025		177,766,541		177,766		1,457,927		(30,319	)		(12,165	)		(747,425	)		845,787

	June 30, 2024
in k€	Discovery and Preclinical Development¹			Just – Evotec Biologics			Intersegment eliminations			Evotec Group
Revenues²		302,379			88,471			—			390,850
Intersegment revenues		—			453			(453	)		—
Costs of revenue		(259,536	)		(81,017	)		204			(340,348	)
Gross profit		42,843			7,907			(249	)		50,501

Operating income and (expenses)
Research and development expenses		(29,348	)		(154	)		249			(29,253	)
Selling, general and administrative expenses		(74,859	)		(17,046	)		—			(91,905	)
Other operating income		23,127			1,106			—			24,233
Other operating expenses		(7,933	)		—			—			(7,933	)
Reorganization costs		(67,447	)		(1,009	)		—			(68,456	)
Total operating income (expenses)		(156,460	)		(17,104	)		249			(173,314	)
Operating income (loss)		(113,617	)		(9,196	)		—			(122,813	)

	Six months ended 30 June 2024
in k€	Discovery and Preclinical Development¹		Just – Evotec Biologics		Total
Revenues from contracts with customers
Fee for service and FTE-based research payments		252,896		88,471		341,367
Recharges²		41,952		—		41,952
Compound access fees		304		—		304
Milestone fees		—		—		—
Licenses		133		—		133
Total revenue from contracts with customers		295,286		88,471		383,757

Timing of revenue recognition
At a point in time		41,952		25,961		67,913
Over a period of time		253,334		62,510		315,843
Total revenue from contracts with customers		295,286		88,471		383,757

Revenues by region
USA		180,261		42,486		222,747
Germany		14,271		—		14,271
France		10,100		—		10,100
United Kingdom		42,616		70		42,687
Switzerland		10,927		45,607		56,534
Rest of the World		37,111		307		37,418
Total revenue from contracts with customers		295,286		88,471		383,757

Revenue from contributions		7,093		—		7,093
Total Revenue		302,379		88,471		390,850

Shares in thousands	30/6/2025			31/12/2024
Issued shares 1. Jan.		177,553,456			177,185,736
Treasury shares 1. Jan.		(167,415	)		(249,915	)
Effect of weighted average capital increase		—			—
Effect of weighted average stock options exercised		175,658			359,413
Weighted Average Number of Shares Outstanding		177,561,699			177,295,234

	June 30, 2025
in k€	Carrying amount			Fair value			Level 1		Level 2		Level 3
Financial assets
Equity instruments		41,177			41,177			—		20,507		20,670
Other financial assets		—			—			—		—		—
Derivative financial instruments		5,971			5,971			—		5,971		—
Financial assets carried at FVTPL		47,148			47,148			—		26,478		20,670
Equity instruments		1,563			1,563			1,563		—		—
Short-term investments¹		83,790			83,790			83,790		—		—
Financial assets carried at FVTOCI		85,353			85,353			85,353		—		—
Financial assets carried at fair value		132,500			132,500			85,353		26,478		20,670
Cash and cash equivalents		264,211			264,211			—		—		—
Receivables and Contract Assets		134,021			134,021			—		—		—
Other financial assets		9,038			9,038			—		—		—
Carried at (amortized) costs		407,270			407,270			—		—		—
Total financial assets		539,770			539,770			85,353		26,478		20,670

Financial liabilities
Derivative financial instruments		—			—			—		—		—
Financial Liabilities carried at FVTPL		—			—			—		—		—
Financial liabilities carried at fair value		—			—			—		—		—
Trade account payables		(57,984	)		(57,984	)		—		—		—
Loans and borrowings		(324,582	)		(282,604	)		—		—		—
Other liabilities		(138,660	)		(138,660	)		—		—		—
Carried at (amortized) costs		(521,226	)		(479,249	)		—		—		—
Total financial liabilities		(521,226	)		(479,249	)		—		—		—

	December 31, 2024
in k€	Carrying amount			Fair value			Level 1		Level 2			Level 3
Financial assets
Equity instruments		31,962			31,962			—		12,180			19,781
Other financial assets		2,127			2,127			—		—			2,127
Derivative financial instruments		—			—			—		—			—
Financial assets carried at FVTPL		34,089			34,089			—		12,180			21,909
Equity instruments		2,409			2,409			2,409		—			—
Short-term investments¹		93,975			93,975			93,975		—			—
Financial assets carried at FVTOCI		96,384			96,384			96,384		—			—
Financial assets carried at fair value		130,472			130,472			96,384		12,180			21,909
Cash and cash equivalents		302,825			302,825			—		—			—
Receivables and Contract Assets		162,353			162,353			—		—			—
Other financial assets		11,259			11,270			—		—			—
Carried at (amortized) costs		476,437			476,437			—		—			—
Total financial assets		606,909			606,909			96,384		12,180			21,909

Financial liabilities
Derivative financial instruments		(4,139	)		(4,139	)		—		(4,139	)		—
Financial Liabilities carried at FVTPL		(4,139	)		(4,139	)		—		(4,139	)		—
Financial liabilities carried at fair value		(4,139	)		(4,139	)		—		(4,139	)		—
Trade account payables		(85,792	)		(85,792	)		—		—			—
Loans and borrowings		(287,556	)		(253,245	)		—		—			—
Other liabilities		(153,175	)		(153,175	)		—		—			—
Carried at (amortized) costs		(526,523	)		(492,213	)		—		—			—
Total financial liabilities		(530,663	)		(496,352	)		—		(4,139	)		—

in k€	Equity Instruments and other financial assets			*Contingent* *Consideration*
Balance as of January 1, 2025		21,909			—
Additions		2,948			—
Disposals		—			—
Transfer from Level 2 to Level 3		—			—
Transfer from Level 3 to Level 2		(1,177	)		—
Fair Value Change through P&L		(3,009	)		—
Conversion of loans to Investments in associates and Joint ventures		—			—
Balance as of June 30, 2025		20,670			—

in k€	Investments			Contingent consideration
Balance as of January 1, 2024		40,328			(311	)
Additions		11,749			—
Disposal		—			311
Transfer from Level 2 to Level 3		9,543			—
Transfer from Level 3 to Level 2		(6,750	)		—
Fair Value Change through P&L		(32,161	)		—
Conversion of loans to Investments in associates and Joint ventures		(800	)		—
Balance as of December 31, 2024		21,909			—

Expected dividend yield	—	%
Expected volatility of Evotec share	87.00	%
Risk-free interest rate	2.18	%
Expected life of share options (years)	4

August 13, 2025


Dr Christian Wojczewski		Aurélie Dalbiez

Chief Executive Officer		Chief People Officer


Dr Cord Dohrmann		Paul Hitchin

Chief Scientific Officer		Chief Financial Officer